One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in drug development
Blog Page 2
Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes in clinical development
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia vera despite standard-of-care therapies
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic castration-resistant prostate cancer
Hope rises for patients with relapsed or refractory acute myeloid leukemia carrying the NPM1 mutation as revumenib moves closer to approval
The Reporter Newsletter
Expert picks and exclusive
deals, in your inbox.
Most Viewed
1
2
3
4
5